AU2015213486B2 - Biomarker signature method, and apparatus and kits therefor - Google Patents

Biomarker signature method, and apparatus and kits therefor Download PDF

Info

Publication number
AU2015213486B2
AU2015213486B2 AU2015213486A AU2015213486A AU2015213486B2 AU 2015213486 B2 AU2015213486 B2 AU 2015213486B2 AU 2015213486 A AU2015213486 A AU 2015213486A AU 2015213486 A AU2015213486 A AU 2015213486A AU 2015213486 B2 AU2015213486 B2 AU 2015213486B2
Authority
AU
Australia
Prior art keywords
biomarker
indicator
determining
irs
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015213486A
Other languages
English (en)
Other versions
AU2015213486A9 (en
AU2015213486A1 (en
Inventor
Richard Bruce Brandon
Leo Charles Mchugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunexpress Pty Ltd
Original Assignee
Immunexpress Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900363A external-priority patent/AU2014900363A0/en
Application filed by Immunexpress Pty Ltd filed Critical Immunexpress Pty Ltd
Priority to AU2015213486A priority Critical patent/AU2015213486B2/en
Publication of AU2015213486A1 publication Critical patent/AU2015213486A1/en
Publication of AU2015213486A9 publication Critical patent/AU2015213486A9/en
Application granted granted Critical
Publication of AU2015213486B2 publication Critical patent/AU2015213486B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Artificial Intelligence (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
AU2015213486A 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor Active AU2015213486B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015213486A AU2015213486B2 (en) 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2014900363 2014-02-06
AU2014900363A AU2014900363A0 (en) 2014-02-06 Biomarker Signature Method, and Apparatus and Kits Therefor
AU2015213486A AU2015213486B2 (en) 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor
PCT/AU2015/050043 WO2015117204A1 (en) 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor

Publications (3)

Publication Number Publication Date
AU2015213486A1 AU2015213486A1 (en) 2016-06-02
AU2015213486A9 AU2015213486A9 (en) 2016-07-07
AU2015213486B2 true AU2015213486B2 (en) 2020-10-22

Family

ID=53754326

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015213486A Active AU2015213486B2 (en) 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor

Country Status (8)

Country Link
US (4) US20150218640A1 (enExample)
EP (1) EP3103046B1 (enExample)
JP (1) JP2017512304A (enExample)
CN (1) CN105981026A (enExample)
AU (1) AU2015213486B2 (enExample)
CA (1) CA2930925A1 (enExample)
DK (1) DK3103046T3 (enExample)
WO (1) WO2015117204A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3103046B1 (en) 2014-02-06 2020-03-25 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
AU2016267392B2 (en) 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
US11884978B2 (en) 2015-09-30 2024-01-30 Immunexpress Pty Ltd Pathogen biomarkers and uses therefor
AU2016349950B2 (en) * 2015-11-06 2022-10-06 Immunexpress Pty Ltd Viral biomarkers and uses therefor
CN106701900B (zh) * 2015-11-16 2020-03-20 上海市东方医院 长链非编码rna herc2p3基因及其在胃癌中的用途
CN105256063B (zh) * 2015-12-01 2019-03-01 北京泱深生物信息技术有限公司 肿瘤标志物dmbx1及其应用
US20200371099A1 (en) 2015-12-24 2020-11-26 Immunexpress Pty Ltd Triage biomarkers and uses therefor
CN105506172B (zh) * 2016-03-01 2019-04-09 北京泱深生物信息技术有限公司 含检测gfod2的骨质疏松血液诊断试剂及其应用
SG11201807719SA (en) * 2016-03-23 2018-10-30 Peach Intellihealth Inc Use of clinical parameters for the prediction of sirs
WO2018035563A1 (en) * 2016-08-24 2018-03-01 Immunexpress Pty Ltd Systemic inflammatory and pathogen biomarkers and uses therefor
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
WO2018085928A1 (en) 2016-11-08 2018-05-17 Qvella Corporation Methods of performing nucleic acid stabilization and separation
CN106755343A (zh) * 2016-12-01 2017-05-31 北京致成生物医学科技有限公司 胰腺癌预后诊断分子标记物
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
WO2018140256A1 (en) * 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
CN108341862B (zh) * 2017-01-24 2021-04-02 上海交通大学医学院附属仁济医院 一种多肽及其应用
CN106947808B (zh) * 2017-03-10 2020-07-24 北京赛尔得生物技术有限公司 Tmem104基因在制备治疗椎间盘退行性疾病药物中的应用
CN107133475B (zh) * 2017-05-10 2020-09-29 浙江省立同德医院 一种中药注射剂不良反应高危患者模式识别方法
US20180357361A1 (en) * 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
EP3710015B1 (en) * 2017-11-15 2024-01-17 Université Laval Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
CN108467890A (zh) * 2018-05-02 2018-08-31 首都医科大学附属北京天坛医院 Vat1基因及vat1基因的干扰物的应用和应用vat1基因的产品
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
WO2020096984A1 (en) * 2018-11-05 2020-05-14 Institute For Systems Biology Sepsis biomarker panels and methods of use
US20210104321A1 (en) * 2018-11-15 2021-04-08 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization
CN113454117B (zh) 2018-12-19 2025-07-04 宾夕法尼亚大学董事会 Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
CN111443065A (zh) * 2019-01-17 2020-07-24 四川大学华西医院 一种肺癌的筛查试剂盒
CN109762911B (zh) * 2019-02-21 2020-12-01 华中农业大学 Ptprj基因作为猪免疫相关性状的分子标记及其应用
WO2020188471A1 (en) * 2019-03-19 2020-09-24 Optina Diagnostics, Inc. Method and system for identifying subjects who are potentially impacted by a medical condition
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
CN110558279B (zh) * 2019-09-16 2021-11-16 南方科技大学 一种药物筛选模型、药物筛选方法及其应用
CN110687285B (zh) * 2019-10-29 2023-03-21 安徽医科大学 诊断试剂盒及mak16在制备系统性红斑狼疮早期诊断试剂中的应用
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
CN111276248B (zh) * 2020-01-20 2023-09-12 苏州帕诺米克生物医药科技有限公司 状态确定系统和电子设备
CN114277138B (zh) * 2020-03-30 2022-06-24 中国医学科学院肿瘤医院 外泌体arpc5、mboat2等在肺癌诊断中的应用
CN114487402A (zh) * 2020-11-12 2022-05-13 首都医科大学附属北京世纪坛医院 尿液非分泌核糖核酸酶蛋白及其多肽片段在妊娠糖尿病中的应用
CN112553322B (zh) * 2020-12-25 2022-07-05 深圳市人民医院 一种骨质疏松诊断标志物及其应用
CN113125757B (zh) * 2021-04-22 2022-10-28 石河子大学 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法
EP4326877A1 (en) * 2021-04-23 2024-02-28 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing chitinase 3-like protein 1/ykl-40 (chi3l1/ykl-40) protein
JP2024520049A (ja) * 2021-05-25 2024-05-21 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 敗血症のエンドタイプおよび／または重症度の診断
EP4423300A4 (en) * 2021-10-29 2025-05-14 Genodx Pty Ltd BIOMARKERS AND THEIR USES
CN114875144A (zh) * 2022-04-02 2022-08-09 及智(苏州)医学技术有限公司 用于评估肿瘤ibc疗法的疗效的生物标志物、系统、方法及试剂盒
WO2023224913A1 (en) * 2022-05-16 2023-11-23 Cz Biohub Sf, Llc Integrated host-microbe metagenomics of cell-free nucleic acid for sepsis diagnosis
EP4471785A1 (fr) * 2023-05-31 2024-12-04 Biomérieux Procede et systeme de typage probabiliste de souches microbiennes
EP4471784A1 (fr) * 2023-05-31 2024-12-04 Biomérieux Procede et systeme de typage probabiliste de souches microbiennes
CN119842884B (zh) * 2025-01-09 2025-09-19 湖北文理学院 Tm9sf1在制备用于监测脓毒症病程的试剂中的应用
CN120405150B (zh) * 2025-07-01 2025-11-18 南昌大学第一附属医院 Itga6在制备脓毒症诊断及病情监测试剂或试剂盒中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060647A2 (en) * 2005-11-25 2007-05-31 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method for detecting or monitoring sepsis by analysing cytokine mrna expression levels

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980488A7 (fi) * 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20070134261A1 (en) 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
MXPA05005072A (es) * 2002-11-12 2005-07-22 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
MXPA05005073A (es) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
EP2366799A3 (de) 2003-04-02 2012-06-20 SIRS-Lab GmbH Verfahren zur in vitro Erkennung schwerer Sepsis
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
EP1673465A4 (en) * 2003-09-29 2008-04-30 Biosite Inc PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
DE102004009952B4 (de) 2004-03-01 2011-06-01 Sirs-Lab Gmbh Verfahren zur Erkennung von Sepsis
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
BRPI0609302A2 (pt) 2005-04-15 2011-10-11 Becton Dickinson Co métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
AU2008294687A1 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in ER- patients
WO2009045443A2 (en) * 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
DE102008000715B9 (de) 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
JP2009229340A (ja) * 2008-03-25 2009-10-08 Sysmex Corp 全身性炎症反応症候群の重症度に関する情報を生成する方法及び装置
NZ628463A (en) * 2009-01-14 2015-12-24 Us Health Ratio based biomarkers and methods for use thereof
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
US20110076685A1 (en) 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110312521A1 (en) * 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
EP2643483A4 (en) * 2010-11-26 2014-04-30 Immunexpress Pty Ltd DIAGNOSTIC AND / OR SCREENING APPROPRIATIONS AND USES THEREFOR
AU2012308365A1 (en) 2011-09-16 2014-04-24 Cepheid Methods of detecting sepsis
EP2931923A1 (en) 2012-12-13 2015-10-21 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3103046B1 (en) 2014-02-06 2020-03-25 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060647A2 (en) * 2005-11-25 2007-05-31 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method for detecting or monitoring sepsis by analysing cytokine mrna expression levels

Also Published As

Publication number Publication date
WO2015117204A1 (en) 2015-08-13
US20150259746A1 (en) 2015-09-17
EP3103046B1 (en) 2020-03-25
CN105981026A (zh) 2016-09-28
US11047010B2 (en) 2021-06-29
DK3103046T3 (da) 2020-06-02
EP3103046A1 (en) 2016-12-14
EP3103046A4 (en) 2017-08-23
US20170191129A1 (en) 2017-07-06
CA2930925A1 (en) 2015-08-13
US20150218640A1 (en) 2015-08-06
US20220325348A1 (en) 2022-10-13
US10865447B2 (en) 2020-12-15
AU2015213486A9 (en) 2016-07-07
AU2015213486A1 (en) 2016-06-02
JP2017512304A (ja) 2017-05-18
WO2015117204A9 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
AU2015213486B2 (en) Biomarker signature method, and apparatus and kits therefor
US12006548B2 (en) Treating or inhibiting severe sepsis based on measuring defensin alpha 4 (DEFA4) expression
EP3931360B1 (en) Systems and methods for using sequencing data for pathogen detection
EP2877605A1 (en) Screening, diagnosis and prognosis of autism and other developmental disorders
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
US20240201186A1 (en) Triage biomarkers and use therefor
US20180321242A1 (en) Viral biomarkers and uses therefor
WO2015117205A1 (en) Biomarker signature method, and apparatus and kits therefor
HK1228037A1 (en) Biomarker signature method, and apparatus and kits therefor

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)